Zenas BioPharma Inc. Common Stock (ZBIO)
Stock · NASDAQ · Health Care
$24.92as of 10/16/2026
Price chart
Active signals
ZBIO Signal Track Record
How signals performed across all stocks →What ZBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 11 | +15.3% | 73% | October 2, 2026 |
| Bollinger Band Breakout | 7 | +17.9% | 86% | August 25, 2026 |
| Bollinger Band Breakdown | 4 | -7.2% | 50% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +23.2% | 100% | June 25, 2026 |
| Any 20-session window (baseline) | +6.5% | 66% |
Computed by MarketWall from daily closing prices since July 2, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus eryt…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 167
- Website
- zenasbio.com/
Fundamentals
- 1-day range
- $24.26$25.94
- Market cap
- $2.03B
- P/E (trailing)
- —
- P/E (forward)
- -5.46
- EPS (trailing)
- $-8.97
- Dividend yield
- —
- Beta
- 0.70
- Avg. volume
- 715.5K
How Zenas BioPharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Zenas BioPharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ZBIOZenas BioPharma Inc. Common Stock$24.84▼ 2.20%Market cap $2.03BP/E —$13.5$44.6
- STOKStoke Therapeutics Inc. Common Stock$24.17▼ 1.79%Market cap $2.06BP/E —$20.32$40.22
- HCMHUTCHMED (China) Limited American Depositary Shares$14.05▲ 0.79%Market cap $2.06BP/E 133.15$15.57$26
- AUPHAurinia Pharmaceuticals Inc Ordinary Shares$16.51▼ 1.31%Market cap $2.10BP/E 7.11$11.21$19.25
- GHRSGH Research PLC Ordinary Shares$18.15▼ 3.51%Market cap $2.10BP/E —$12.04$31.44
- NUVBNuvation Bio Inc. Class A Common Stock$4.45▼ 6.32%Market cap $2.13BP/E —$3.36$9.75
- ABCLAbCellera Biologics Inc. Common Shares$11.8▼ 6.94%Market cap $1.92BP/E —$2.75$15.02
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $24.84 | ▼ 2.20% | $13.5$44.6 |
| STOK Stoke Therapeutics Inc. Common Stock | $2.06B | — | $24.17 | ▼ 1.79% | $20.32$40.22 |
| HCM HUTCHMED (China) Limited American Depositary Shares | $2.06B | 133.15 | $14.05 | ▲ 0.79% | $15.57$26 |
| AUPH Aurinia Pharmaceuticals Inc Ordinary Shares | $2.10B | 7.11 | $16.51 | ▼ 1.31% | $11.21$19.25 |
| GHRS GH Research PLC Ordinary Shares | $2.10B | — | $18.15 | ▼ 3.51% | $12.04$31.44 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $4.45 | ▼ 6.32% | $3.36$9.75 |
| ABCL AbCellera Biologics Inc. Common Shares | $1.92B | — | $11.8 | ▼ 6.94% | $2.75$15.02 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Targetbenzinga · 10/13/2026
- Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48Benzinga · 9/30/2026
- Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price TargetBenzinga · 9/30/2026
- HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price TargetBenzinga · 9/30/2026
- Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease TranscriptSeekingAlpha · 9/30/2026
- Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?Yahoo · 9/23/2026
- Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?Yahoo · 9/23/2026
- Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026Yahoo · 9/22/2026
- Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026Benzinga · 9/22/2026
Insider Activity
Insider Actions →- Oliger Christy J. · September 1, 2026 · Grant37.0K
- ORLOFF JOHN J · June 15, 2026 · Grant18.5K
- Nunn Jason Raleigh · June 15, 2026 · Grant18.5K
- Allen Patricia L · June 15, 2026 · Grant18.5K
- Farmer Joseph L · June 15, 2026 · Grant175.0K
- Patrick G. Enright · June 15, 2026 · Grant18.5K
- Leon O. Moulder Jr. · June 15, 2026 · Grant500.0K
- Leon O. Moulder Jr. · May 18, 2026 · Buy60.0K @ $16.88
- Leon O. Moulder Jr. · April 29, 2026 · Buy35.0K @ $17.62
- Leon O. Moulder Jr. · April 28, 2026 · Buy25.0K @ $18.02
Institutional Ownership
March 31, 2026
- Total shares held
- 55.22M
- Total value held
- $1.08B
- Institutional holders
- 134
- Unknown9.08M
- Unknown5.04M
- Unknown4.02M
- Unknown3.92M
- Unknown3.13M
- Unknown2.55M
- Unknown2.43M
- Unknown2.36M
- Unknown2.04M
- Unknown1.84M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations
The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.